Department of Gastric Surgery, Liaoning Cancer Hospital and Institute, Cancer Hospital of China Medical University, No 44 of Xiaoheyan Road, Dadong District, Shenyang, 110042, China.
Department of Surgical Oncology, First Affiliated Hospital of China Medical University, 155 Nanjing North Street, Heping District, Shenyang, 110001, China.
BMC Cancer. 2022 Apr 30;22(1):474. doi: 10.1186/s12885-022-09541-0.
The Lauren classification of gastric tumors strongly correlates with prognosis. The purpose of this study was to explore the specific molecular mechanism of Lauren classification of gastric cancer and provide a possible theoretical basis for the treatment of gastric cancer.
We standardized the gene expression data of five Gene Expression Omnibus gastric cancer databases and constructed a Weighted Co-expression Network Analysis (WGCNA) model based on clinicopathological information. The overall survival (OS) and disease-free survival (DFS) curves were extracted from the Cancer Genome Atlas (TCGA) and GSE62254 databases. Western blotting was used to measure protein expression in cells and tissues. Scratch and transwell experiments were used to test the migration ability of tumor cells. Immunohistochemistry was used to measure tissue protein expression in clinical tissue samples to correlate to survival data.
The WGCNA model demonstrated that blue cyan was highly correlated with the Lauren classification of the tumor (r = 0.24, P = 7 × 10). A protein-protein interaction network was used to visualize the genes in the blue cyan module. The OS and PFS TCGA analysis revealed that LMOD1 was a gene of interest. The proportion of diffuse gastric cancer patients with high expression of LMOD1 was significantly higher than that of intestinal type patients. LMOD1 promoted the migration of gastric cancer cells by regulating the FAK-Akt/mTOR pathway in vitro. Additionally, a Gene Set Enrichment Analysis using the TCGA and GSE62254 databases, and western blot data, showed that LMOD1 could promote an epithelial-mesenchymal transition (EMT), thus potentially affecting the occurrence of peritoneal metastasis of gastric cancer. Immunohistochemistry showed that LMOD1 was highly expressed in cancer tissues, and the prognosis of patients with high LMOD1 expression was poor.
LMOD1 is an oncogene associated with diffuse gastric cancer and can affect the occurrence and development of EMT by regulating the FAK-Akt/mTOR pathway. LMOD1 can therefore promote peritoneal metastasis of gastric cancer cells and can be used as a novel therapeutic target for gastric cancer.
胃肿瘤的 Lauren 分类与预后密切相关。本研究旨在探讨 Lauren 分类胃癌的具体分子机制,为胃癌的治疗提供可能的理论依据。
我们对 5 个基因表达综合数据库的基因表达数据进行标准化处理,并基于临床病理信息构建了加权共表达网络分析(WGCNA)模型。从癌症基因组图谱(TCGA)和 GSE62254 数据库中提取总生存期(OS)和无病生存期(DFS)曲线。Western blot 用于测量细胞和组织中的蛋白质表达。划痕和 Transwell 实验用于测试肿瘤细胞的迁移能力。免疫组织化学用于测量临床组织样本中的组织蛋白表达,以与生存数据相关联。
WGCNA 模型表明,蓝青色与肿瘤的 Lauren 分类高度相关(r=0.24,P=7×10)。使用蛋白质-蛋白质相互作用网络可视化蓝青色模块中的基因。OS 和 PFS TCGA 分析表明,LMOD1 是一个感兴趣的基因。高表达 LMOD1 的弥漫型胃癌患者比例明显高于肠型患者。LMOD1 通过调节 FAK-Akt/mTOR 通路在体外促进胃癌细胞的迁移。此外,使用 TCGA 和 GSE62254 数据库以及 Western blot 数据进行基因集富集分析表明,LMOD1 可以促进上皮-间充质转化(EMT),从而可能影响胃癌腹膜转移的发生。免疫组织化学显示,LMOD1 在癌组织中高表达,高 LMOD1 表达的患者预后较差。
LMOD1 是一种与弥漫型胃癌相关的癌基因,可通过调节 FAK-Akt/mTOR 通路影响 EMT 的发生和发展。因此,LMOD1 可以促进胃癌细胞的腹膜转移,可作为胃癌的一种新的治疗靶点。